Alexandria Venture Investments participated in a $30m round for the gene therapy technology developer, which will use the capital to expand its partnerships.

US-based cell therapy technology developer Kytopen picked up $30m on Tuesday in a series A round featuring Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities.

Northpond Ventures led the oversubscribed round, which also attracted Horizons Ventures, Mass Ventures, The Engine and private investors Michael Chambers and John Ballantyne.

Kytopen is working on scalable technology that facilitates the non-viral manufacturing of cell therapies in a matter of days rather than the weeks required by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn